DuoDote.com

After Injecting [1]

Remove the DuoDote™ Auto-Injector from the thigh and look at the Green Tip. If the needle is visible, the drug has been administered. If the needle is not visible, check to be sure the Gray Safety Release has been removed and repeat the previous steps beginning with Step 4, but push harder in Step 5.
After the drug has been administered, push the needle against a hard surface to bend the needle back against the DuoDote Auto-Injector.
Put the used DuoDote Auto-Injector back into the plastic pouch, if available. Leave used DuoDote Auto-Injector(s) with the patient to allow other medical personnel to see the number of DuoDote Auto-Injectors administered.
Immediately move yourself and the patient away from the contaminated area and seek definitive medical care for the patient.

Before Injecting | Select Site and Inject | After Injecting

The DuoDote™ Auto-Injector (atropine 2.1 mg/0.7 mL and pralidoxime chloride 600 mg/2 mL) is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides.

IMPORTANT SAFETY INFORMATION

The DuoDote Auto-Injector is intended as an initial treatment of the symptoms of organophosphorus insecticide or nerve agent poisonings; definitive medical care should be sought immediately. The DuoDote Auto-Injector should be administered by Emergency Medical Services personnel who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication.

Individuals should not rely solely upon agents such as atropine and pralidoxime to provide complete protection from chemical nerve agents and insecticide poisoning. Primary protection against exposure to chemical nerve agents and insecticide poisoning is the wearing of protective garments including masks designed specifically for this use. Evacuation and decontamination procedures should be undertaken as soon as possible. Medical Personnel assisting evacuated victims of nerve agent poisoning should avoid contaminating themselves by exposure to the victim's clothing.

In the presence of life-threatening poisoning by organophosphorus nerve agents or insecticides, there are no absolute contraindications to the use of the DuoDote Auto-Injector. When symptoms of poisoning are not severe, DuoDote Auto-Injector should be used with extreme caution in people with heart disease, arrhythmias, recent myocardial infarction, severe narrow angle glaucoma, pyloric stenosis, prostatic hypertrophy, significant renal insufficiency, chronic pulmonary disease, or hypersensitivity to any component of the product.

Please click here to view full prescribing information for DuoDote.

DuoDote Auto-Injector, the DuoDote Logo, Mark I Kit, and BinaJect are trademarks of Meridian Medical Technologies™, Inc., a wholly owned subsidiary of King Pharmaceuticals^®, Inc. Copyright ® 2010 Meridian Medical Technologies™, Inc., a wholly owned subsidiary of King Pharmaceuticals^®, Inc. All rights reserved. MMT6193 06/2009